For several reasons, but mainly the better pipeline of drug candidates. OREX is in trouble. I did not think that was the case after the initial leak, I actually thought that was a brilliant marketing strategy, but failure to disclose the trend reversal with the 2nd 25% is a big problem and Takeda may/should walk. IMO of course.
you should read "Options as a strategic Investment" before trading options. I love to sell to newbies that buy calls puts.
Interesting, I noticed the former IR leader from ARNA (David) was listed as a communications consultant on the OREX PR. ARNA should have hired him back, but maybe he was not interested, or maybe he did not tolerate Jack.
I was not taking the OREX early news release problem serious when it was first mentioned, but today the issue took a serious negative turn for them when it was disclosed that the 2nd - 25% was not like the 1st - 25%. If they released only the first 25% as it appears they did, when they also knew the results of the 2nd 25% they have a serious ethics issue that could cause more problem for either the company, certain execs, or both.
doubtful, Nissan is highly respected. He was the only objector on the AFFY panel meeting. Most of the panel voted for approval, he went against them. The product was approved and later pulled. I think AFFY's partner was Takeda??? When it comes to cardio related trials, he's the gold standard.
S9, how do i find your web site. I had to laugh about JDS. When I told him he had his nose up JL's rear about 1-2 years ago he wanted to fight me (on-line of course). The guy is a little late to the anti JL party and not very mature.
how does one find said web site. I want to see how much GILD will pay! If you can predict when someone, anyone will pay up, that would be something.
as you know, these studies are a challenge and they take a long time, so it will be years before we have any meaningful results/progress/value on this one. On the + side, ACAD turned their drug into a multi $BB co.
dreamers, I hope you are right. I don't think we will wake up from a $4 stock price to see this, price will have to go up first. No company can afford the bad PR of $12+ for a stock currently priced at $4. So, first the price will rise to $6-8, then maybe a deal...some day.
I had the same observation, what kind of deal did they sign? 22.5MM seems like far more revs than they have produced. Are we selling for a loss and making it up with volume? This is a bit concerning. Frankly, I was not impressed with the call, nothing new other than the tiny deal for an old drug.
another poster said it's an old drug that was tried and failed, so we need to get the accurate facts, maybe this is similar, but a new formulation? Nupi failed early trials.
This was the only bright spot on the cc, everything else is far away...All new Belviq trials are waiting on XR. They are too busy to provide details on 334. Something else might not happen this year (missed the details on that one) due to budget or priority...Overall I found this call lacking in progress and detail, a weak effort.
recall, the first trials that ACAD did failed due to a placebo effect and poor control (trial design is challenging in this area). Don't know about 125, but it's something they need to study in great detail when designing the studies.